AU2534795A - Combination product of dichloroacetic acid and an nmda antagonist - Google Patents

Combination product of dichloroacetic acid and an nmda antagonist

Info

Publication number
AU2534795A
AU2534795A AU25347/95A AU2534795A AU2534795A AU 2534795 A AU2534795 A AU 2534795A AU 25347/95 A AU25347/95 A AU 25347/95A AU 2534795 A AU2534795 A AU 2534795A AU 2534795 A AU2534795 A AU 2534795A
Authority
AU
Australia
Prior art keywords
combination product
dichloroacetic acid
nmda antagonist
nmda
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25347/95A
Other languages
English (en)
Inventor
Rodney Brown
Stephen Curry
Robert John Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Corp
Original Assignee
Fisons Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Corp filed Critical Fisons Corp
Publication of AU2534795A publication Critical patent/AU2534795A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU25347/95A 1994-05-24 1995-05-24 Combination product of dichloroacetic acid and an nmda antagonist Abandoned AU2534795A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9410320 1994-05-24
GB9410320A GB9410320D0 (en) 1994-05-24 1994-05-24 Novel therapeutic method
PCT/GB1995/001205 WO1995031986A1 (fr) 1994-05-24 1995-05-24 Produit combine d'acide dichloroacetique et d'antagoniste de nmda

Publications (1)

Publication Number Publication Date
AU2534795A true AU2534795A (en) 1995-12-18

Family

ID=10755581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25347/95A Abandoned AU2534795A (en) 1994-05-24 1995-05-24 Combination product of dichloroacetic acid and an nmda antagonist

Country Status (3)

Country Link
AU (1) AU2534795A (fr)
GB (1) GB9410320D0 (fr)
WO (1) WO1995031986A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908462A3 (fr) * 2002-06-20 2008-06-25 The Governors Of The University Of Alberta Dichloroacetate en combinaison avec des medicaments cardioprotecteurs ou hemodynamiques
US20040039055A1 (en) * 2002-06-20 2004-02-26 Lopaschuk Gary D. Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs
US6693133B1 (en) 2002-10-07 2004-02-17 University Of Alberta Methods of cardioprotection using dichloroacetate in combination with an inotrope
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
DE602004028046D1 (de) * 2004-01-16 2010-08-19 Univ Alberta Dichloroazetat zusammen mit einem inotropen medikament zur cardioprotektion
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
CA2679446C (fr) 2007-03-01 2016-05-17 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631294A (en) * 1985-07-05 1986-12-23 University E.M., Inc. Treatment of cerebral ischemia with dichloroacetate
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties

Also Published As

Publication number Publication date
GB9410320D0 (en) 1994-07-13
WO1995031986A1 (fr) 1995-11-30

Similar Documents

Publication Publication Date Title
EP0784933A3 (fr) Libération prolongée d'additifs dans des produits comestibles
IL117265A0 (en) Benzazepine- benzoxazepine- and benzothiazepine-n-acetic acid derivatives their preparation and pharmaceutical compositions containing them
AU3119495A (en) Surgical product and its use
IL118825A (en) Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use
IL116851A (en) 3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them
AU2995892A (en) Physiological tear compositions and methods for their preparation
AU4597596A (en) Prevention of protein aggregation
AU1249597A (en) Preparation of inulin products
IL119078A (en) Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them
IL117860A0 (en) Substituted 1-phenyl-3-pyrazolecarboxamides their preparation and pharmaceutical compositions containing them
IL122293A0 (en) Substituted 4-phenylaminothiazoles their preparation and pharmaceutical compositions containing them
AU2534795A (en) Combination product of dichloroacetic acid and an nmda antagonist
IL119559A0 (en) Purin -6- one derivatives their preparation and pharmaceutical compositions containing them
IL129089A0 (en) New derivatives from piperidine-keto acid their preparation and use
AU7163798A (en) A novel dietary formulation comprising arachidonic acid and methods of use
IL123611A0 (en) Novel amino acid derivatives their preparation and use
AU5856898A (en) Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them
AU2626895A (en) Production and uses of caffeic acid and derivatives thereof
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
IL116480A0 (en) Acetic acid deriratives their preparation and pharmaceutical compositions containing them
HUP9602196A2 (en) Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof
IL117397A (en) Substituted naphthyl compounds and pharmaceutical compositions comprising them
AU5497796A (en) New hydroximic acid derivatives
AU6641896A (en) Infant formula and infant formula additives
EP0747351A3 (fr) Lipides thiocationiques, compositions pharmaceutiques et leurs méthodes d'utilisation